Cennerv lodges prelim offer documents for Catalist listing, to acquire US subsidiary with proceeds

-A +A

SINGAPORE (Sept 21): Cennerv Pharmaceuticals on Wednesday lodged its preliminary prospectus ahead of its planned initial public offering (IPO) on the SGX Catalist board.

Cennerv is a Singapore-based pharmaceutical developer specialising in treatments for central nervous system (CNS) disorders with a focus on depression, insomnia, dementia, schizophrenia and autism.

The company intends to use a portion of its proceeds from the exercise to acquire a further 13 million units of Gemeni Therapeutics LLC, a US-based... (Click here to read the full story)